



IFW  
#

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS  
FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:  
COMMISSIONER OF PATENTS, P.O. BOX 1450, ALEXANDRIA, VA  
22313-1450, ON  
18 NOVEMBER 2004

*Deborah P. Pugh*

DATE

11/18/04

NAME OF PERSON MAILING DOCUMENT

Attorney Docket No.: P31332-1C3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Turner, *et al.* 18 November 2004  
Serial No.: 10/631,051 Group Art Unit: 1614  
Filed: 24 July 2003 Examiner: Phyllis Spivak  
For: Use of Nitric Oxide Synthase Inhibitors for the Treatment of  
Diabetes

Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO NOTICE OF RESTRICTION REQUIREMENT UNDER**  
**37 C.F.R. §1.143**


Sir:

This paper is in response to the Office Action dated 18 June 2004, setting forth a thirty (30) day shortened statutory period for reply. This response is being filed after said period, and Applicants file herewith a Request for a Four Month Extension of Time in this case. Authorization is hereby given to deduct any other requisite fees required by this paper to Deposit Account No. 19-2570.

Claims 1-8 are subject to a restriction requirement. Upon review of the Detailed Action provided by the Examiner, Applicants provisionally elect the species aminoguanidine, with traverse.

Applicants retain the right to file divisional applications on the non-elected subject matter, or any other claims supported by the instant specification, should the restriction requirement become final.

Respectfully submitted,



Edward R. Ginnami  
Attorney for Applicants  
Reg. No. 38,891

GlaxoSmithKline  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Telephone No.:(610) 270-4478  
Facsimile No.:(610) 270-5090  
N:\ERG\APPS\IP31332-1C2\C3\restreq.DOC